Ampio updates Ampion regulatory progress

Ampio updates Ampion regulatory progress

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is providing an update of the regulatory and clinical path activities required to file a Biologics License Application (BLA) for Ampion... Read More

Monday November 12, 2018 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Mike Macaluso

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

Ampio: Ampion achieves major decrease in patient osteoarthritis knee pain

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) reported that the Phase 3 clinical trial of Ampion met its primary endpoint with 71% of Ampion treated patients meeting the... Read More

Friday December 15, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

Ampio Pharmaceuticals announces allowance of composition and methods patent for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) today announced the allowance of an important composition and methods patent in the U.S. complimenting a series of patents on Ampion... Read More

Tuesday August 8, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Michael Macaluso, Ampion

Ampio Pharmaceuticals selling $6.3M in stock to fund Ampion clinical tests

Ampio Pharmaceuticals selling $6.3M in stock to fund Ampion clinical tests

ENGLEWOOD -- A mpio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced it has entered into a securities purchase agreement with investors providing for the registered sale of approximately... Read More

Monday June 5, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio initiates pivotal Ampion osteoarthritis trial

Ampio initiates pivotal Ampion osteoarthritis trial

ENGLEWOOD -- Ampio Pharmaceuticals, Inc . (NYSE MKT: AMPE) announced it has begun a single injection study to meet the unmet medical need of treating the severe pain and loss of function... Read More

Monday May 1, 2017 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Dr. David Bar-Or, Chris Ehrlich, Michael Macaluso

Ampio: FDA discussions continue on best path forward for Ampion

Ampio: FDA discussions continue on best path forward for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it is continuing discussions with the CBER Division of the FDA to determine the best path forward to obtain a Biological... Read More

Thursday November 10, 2016 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA

Ampio Pharmaceuticals announces stock sale to investor to raise $3.75M

Ampio Pharmaceuticals announces stock sale to investor to raise $3.75M

ENGLEWOOD -- Ampio Pharmaceuticals , Inc. (NYSE MKT: AMPE) announced it has entered into a securities purchase agreement with an institutional investor providing for the registered sale of... Read More

Thursday September 1, 2016 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion

Ampio Pharmaceuticals announces mostly positive results for Ampion

Ampio Pharmaceuticals announces mostly positive results for Ampion

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE MKT:AMPE) announced the results of the Ampion PIVOT clinical trial as well as a comprehensive analysis that integrates trial data from three single... Read More

Friday July 1, 2016 0 comments Tags: Englewood, Ampio Pharmaceutical, Ampion, Michael Macaluso